2-oxoisovalerate dehydrogenase subunit alpha (BCKDHA) (BCKDHA)

2-oxoisovalerate dehydrogenase subunit alpha (BCKDHA) is a critical component of the mitochondrial branched-chain alpha-keto acid dehydrogenase (BCKD) complex, which catalyzes the rate-limiting step in the catabolism of branched-chain amino acids (BCAAs) such as leucine, isoleucine, and valine [1.3.3, 1.3.5]. As the alpha subunit of the E1 decarboxylase component, BCKDHA is essential for the oxidative decarboxylation of alpha-ketoacids into their corresponding acyl-CoA derivatives, a process that requires thiamine pyrophosphate as a cofactor [1.3.3, 1.4.2]. Mutations in the BCKDHA gene are the primary cause of Maple Syrup Urine Disease (MSUD) Type IA, a severe metabolic disorder where the accumulation of BCAAs and their toxic ketoacid byproducts leads to neurotoxicity, developmental delays, and potentially fatal metabolic crises [1.3.1, 1.5.1]. Beyond its role in MSUD, BCKDHA activity is increasingly recognized as a factor in systemic metabolic diseases; reduced activity is associated with obesity, type 2 diabetes, and heart failure due to the buildup of BCAAs which can impair insulin signaling [1.2.4, 1.3.2]. Therapeutic interventions include thiamine supplementation for responsive variants and the use of sodium phenylbutyrate, which indirectly increases BCKDHA activity by inhibiting the regulatory kinase BCKDK [1.2.2, 1.2.4]. Monitoring of patients typically involves measuring plasma levels of alloisoleucine and other BCAAs as biomarkers of enzyme function and metabolic control [1.1.2, 1.3.4].

Other names

BCKDH E1-alphaBCKDE1AOVD1AMSUD1MSUBranched-chain alpha-keto acid dehydrogenase E1 component alpha chain2-oxoisovalerate dehydrogenase (lipoamide)

Sodium phenylbutyrate acts as an allosteric inhibitor of branched-chain alpha-keto acid dehydrogenase kinase (BCKDK), which normally phosphorylates and inactivates BCKDHA; by inhibiting the kinase, phenylbutyrate promotes the dephosphorylated, active state of the BCKD complex [1.2.2, 1.2.4]. Thiamine (as thiamine pyrophosphate) serves as an essential cofactor for the E1 subunit's decarboxylase activity, and high doses can stabilize certain mutant forms of the enzyme [1.3.3, 1.3.4].